证券代码：688189 证券简称：南新制药 公告编号：2025-049 一、募集资金基本情况 根据中国证监会于 2020 年 2 月 25 日出具的《关于同意湖南南新制药股份有 限公司首次公开发行股票注册的批复》（证监许可[2020]318 号），同意湖南南新 制药股份有限公司（以下简称"公司"）首次公开发行股票的注册申请。公司首 次公开发行人民币普通股 3,500 万股，发行价格为 34.94 元/股，募集资金总额 为人民币 122,290.00 万元，扣除发行费用合计人民币 8,761.77 万元（不含增值 税）后，实际募集资金净额为人民币 113,528.23 万元。上述募集资金已于 2020 年 3 月 20 日全部到位，由天职国际会计师事务所（特殊普通合伙）对本次发行 募集资金的到账情况进行了审验，并出具了（天职业字[2020]16008 号）《验资 报告》。 湖南南新制药股份有限公司 关于使用部分闲置募集资金临时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 临时补流募集资金 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-050 湖南南新制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 3 日（星期一）至 11 月 9 日（星期日）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过湖南南新制药股份 有限公司（以下简称"公司"）邮箱 nanxin@nucien.com 进行提问。公司将在说 明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）披 露了公司《2025 年第三季度报告》。为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果和财务状况，公司计划于 2025 年 11 月 10 日（星期一） 9:00-10:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 20 ...

西部证券股份有限公司 关于湖南南新制药股份有限公司 使用部分闲置募集资金临时补充流动资金的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南南新制 药股份有限公司（以下简称"南新制药"或"公司"）首次公开发行股票并在科创 板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则（2025年4月修订）》《上市公司募集资金监管规则》《上海证券交易 所科创板上市公司自律监管指引第1号——规范运作（2025年5月修订）》以及《上海 证券交易所上市公司自律监管指引第11号——持续督导 （2025年3月修订）》等相关 规定履行持续督导职责，对南新制药拟使用闲置募集资金临时补充流动资金事项进 行了核查，核查情况及核查意见如下： 一、募集资金基本情况 | 发行名称 | 2020 | | 年首次公开发行股份 | | | --- | --- | --- | --- | --- | | 募集资金总额 | 122,290.00 | | 万元 | | | 募集资金净额 | 113,528.23 | | 万元 | | | 募集资金到账时间 | 2020 年 | 3 | 月 20 | ...

Core Insights - Nanjing Pharmaceutical experienced a 5.23% increase in stock price, reaching 8.86 CNY per share, with a trading volume of 15.72 million CNY and a market capitalization of 2.43 billion CNY [1] Company Overview - Hunan Nanjing Pharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, established on December 27, 2006, and listed on March 26, 2020. The company focuses on the research, production, and sales of antiviral and infectious disease prevention drugs, as well as treatments for major diseases like cardiovascular diseases and diabetes. Its main business revenue is derived entirely from chemical drug formulations, accounting for 100% [1] Shareholder Information - Dazhong Fund's Dazhong Jingheng Mixed A (090019) is among the top ten circulating shareholders of Nanjing Pharmaceutical, holding 2.9738 million shares, unchanged from the previous period, representing 1.08% of circulating shares. The estimated floating profit today is approximately 1.3085 million CNY [2] Fund Performance - Dazhong Jingheng Mixed A (090019) was established on June 15, 2012, with a latest scale of 397 million CNY. Year-to-date returns are 39.82%, ranking 1849 out of 8226 in its category. Over the past year, returns are 52.22%, ranking 848 out of 8099, and since inception, returns have reached 369.48% [2] Fund Manager Information - The fund manager of Dazhong Jingheng Mixed A (090019) is Su Bingyi, who has a cumulative tenure of 13 years and 265 days. The total asset scale of the fund is 1.24 billion CNY, with the best fund return during his tenure being 245.86% and the worst being -71.74% [3] Fund Holdings - Dazhong Jingheng Mixed A (090019) has Nanjing Pharmaceutical as its second-largest holding, with 2.9738 million shares, unchanged from the previous period, representing 2.67% of the fund's net value. The estimated floating profit today is approximately 1.3085 million CNY [4]

Core Insights - The chemical products sector experienced a slight increase of 0.11% on October 24, with Boyuan Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Sector Performance - Boyuan Co., Ltd. (301617) closed at 102.79, with a significant increase of 14.34% and a trading volume of 91,000 shares, resulting in a transaction value of 902 million yuan [1] - Yahua Group (002497) saw a rise of 10.03%, closing at 17.88 with a trading volume of 1.2768 million shares [1] - Licheng Industrial (001218) increased by 6.97%, closing at 23.78 with a trading volume of 95,700 shares [1] - Guangdong Hongda (002683) rose by 4.77%, closing at 39.94 with a trading volume of 237,200 shares [1] - Other notable performers include Shengda Biological (603079) up 4.29%, Jianlong Micro-Nano (688357) up 4.04%, and Gaodian New Materials (300200) up 3.86% [1] Capital Flow - The chemical products sector saw a net outflow of 291 million yuan from main funds, while retail investors contributed a net inflow of 379 million yuan [1]

Group 1: New Stock Offerings - The tender offer for Shangwei New Materials (688585) is open from September 29, 2025, to October 28, 2025[1] - Huajian Group (600629) announced significant updates on October 22, 2025[1] - ST Dongyi (002713) reported on October 22, 2025, regarding its stock status[1] Group 2: Stock Volatility Alerts - Dayou Energy (600403) experienced severe abnormal fluctuations, with updates on October 22 and 23, 2025[1] - Multiple companies, including Tianpu Co. (605255) and Guangming Real Estate (600708), reported abnormal trading activities on October 23, 2025[1] - ST Nanzhi (002305) and ST Aowei (002231) are under scrutiny for unusual market behavior as of October 23, 2025[1]

Core Viewpoint - The A-share market continues to see an upward trend in flu-related stocks, driven by rising flu activity and concerns over a potentially severe flu season this year [1] Group 1: Stock Performance - Hendi Pharmaceutical has seen a rise of over 18% - Dori Pharmaceutical has increased by over 11% - Guangji Pharmaceutical and Te Yi Pharmaceutical have hit the 10% daily limit up - Chenxin Pharmaceutical has also increased by over 6% - Notably, Guangji Pharmaceutical has achieved two consecutive limit-up days [1] Group 2: Flu Activity and Expert Insights - The China CDC reported that flu activity in northern provinces is currently low, while southern provinces are experiencing an increase - Overall, respiratory disease incidence is showing a slow upward trend nationwide - Experts indicate that the main flu strain this year is likely to be the H3N2 subtype, which was largely absent last year, leading to lower immunity levels in the population - Many experts believe that this year's flu season may arrive earlier and result in a higher number of infections [1]

Group 1 - The company has cumulatively repaid RMB 100 million of temporarily supplemented working capital as of October 21, 2025 [1] - The company decided to use up to RMB 100 million of idle raised funds to temporarily supplement working capital to improve fund utilization efficiency, increase company earnings, reduce financial costs, and lower operational costs [1] - The temporary use of idle funds is limited to a period not exceeding 12 months from the date of board approval, with a commitment to return the funds to the special account if necessary [1] Group 2 - As of the announcement date, the company has fully repaid the idle raised funds used for temporary working capital [2] - The company has notified its sponsor institution and the sponsor representative about the repayment of the raised funds [2]

证券代码：688189 证券简称：南新制药 公告编号：2025-048 湖南南新制药股份有限公司 关于提前归还临时用于补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 2025年10月21日，公司将上述暂时补充流动资金的10,000.00万元提前归还至募集资金专用账户。截至本 公告披露日，公司用于暂时补充流动资金的闲置募集资金已全部归还。公司已将上述募集资金的归还情 况通知了公司的保荐机构及保荐代表人。 特此公告。 湖南南新制药股份有限公司董事会 2025年10月22日 ● 截至2025年10月21日，公司已累计归还临时补充流动资金的闲置募集资金人民币10,000.00万元。 一、募集资金临时补充流动资金情况 ■ 湖南南新制药股份有限公司（以下简称"公司"）于2024年12月11日召开第二届董事会第十四次会议和第 二届监事会第十二次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》。为提 高募集资金使用效率，增加公司收益，减少公司财务费用，降低公司运营成本，维护公 ...

New Stock Offerings - The tender offer for Shangwei New Materials (688585) is open from September 29, 2025, to October 28, 2025[1] - BoRui Pharmaceutical (688166) and Nanxin Pharmaceutical (688189) announced significant abnormal fluctuations on October 10, 2025[1] - Tianpu Co., Ltd. (605255) and Pingtan Development (000592) issued announcements on October 21, 2025[1] Market Alerts - Multiple companies, including AnTong Holdings (600179) and GuoXin New Energy (600617), issued announcements on October 21, 2025, regarding their stock performance[1] - A total of 20 companies reported abnormal fluctuations in their stock prices, indicating potential volatility in the market[2] - The report highlights the importance of monitoring these fluctuations for investment strategies and risk management[2]